–All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309). –Results support onabotulinumtoxinA as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback